Yasutomo Fujii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yasutomo Fujii has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hiromu Ito
Department of Orthopaedics, Kurashiki Central Hospital, Kurashiki, Okayama, Japan
1 shared publication - Michiko Kasahara
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukiga-oka, Tsukuba, Ibaraki, 305-8585, Japan; Alliance Laboratory for Advanced Medical Research, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan
1 shared publication - Motomu Hashimoto
Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-Ku, Osaka 545-8585, Japan
1 shared publication - Shingo Sugahara
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukiga-oka, Tsukuba, Ibaraki, 305-8585, Japan
1 shared publication - Shuh Narumiya
Department of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication Takanori Sengoku
1 shared publication
Latest Publications
- Open Access
- 1 September 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 882, 173238
Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib
- 1 September 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 882, 173238
Open AccessRole of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib
- 11 March 2013
- Published by S. Karger AG in Pharmacology
- Vol. 91 (3-4) , 207-213
Effects of the Janus Kinase Inhibitor CP-690550 (Tofacitinib) in a Rat Model of Oxazolone-Induced Chronic Dermatitis
The effect of CP-690550 (tofacitinib), a new Janus kinase (JAK) inhibitor, was evaluated in chronic allergic dermatitis. Allergic contact dermatitis was induced in rat ears by repeated application of oxazolone. This dermatitis was accompanied by sustained ear swelling and marked epidermal hyperplasia. In the induced ear, a lot of inflammatory cells infiltrated into the dermis site and the amounts of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-22 were elevated. Orally administered CP-690550 significantly suppressed ear swelling as well as epidermal thickening, and the effect at 10 mg/kg was comparable to that of cyclosporin A and etanercept. These results suggest a great potential of CP-690550, a JAK inhibitor, as a treatment for chronic dermatitis featuring epidermal hyperplasia (in the pathogenesis of which IFN-γ, TNF-α and IL-22 play a role) such as psoriasis and chronic atopic dermatitis.
- 11 March 2013
- Published by S. Karger AG in Pharmacology
- Vol. 91 (3-4) , 207-213
Effects of the Janus Kinase Inhibitor CP-690550 (Tofacitinib) in a Rat Model of Oxazolone-Induced Chronic Dermatitis
The effect of CP-690550 (tofacitinib), a new Janus kinase (JAK) inhibitor, was evaluated in chronic allergic dermatitis. Allergic contact dermatitis was induced in rat ears by repeated application of oxazolone. This dermatitis was accompanied by sustained ear swelling and marked epidermal hyperplasia. In the induced ear, a lot of inflammatory cells infiltrated into the dermis site and the amounts of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-22 were elevated. Orally administered CP-690550 significantly suppressed ear swelling as well as epidermal thickening, and the effect at 10 mg/kg was comparable to that of cyclosporin A and etanercept. These results suggest a great potential of CP-690550, a JAK inhibitor, as a treatment for chronic dermatitis featuring epidermal hyperplasia (in the pathogenesis of which IFN-γ, TNF-α and IL-22 play a role) such as psoriasis and chronic atopic dermatitis.